Literature DB >> 35747791

Emerging Role of MicroRNAs in the Therapeutic Response in Cervical Cancer: A Systematic Review.

Gloria Ravegnini1, Francesca Gorini1, Giulia Dondi2,3, Marco Tesei2, Eugenia De Crescenzo2,3, Alessio G Morganti4, Patrizia Hrelia1, Pierandrea De Iaco2,3, Sabrina Angelini1, Anna Myriam Perrone2,3.   

Abstract

Cervical cancer is a common female cancer, with nearly 600,000 cases and more than 300,000 deaths worldwide every year. From a clinical point of view, surgery plays a key role in early cancer management, whereas advanced stages are treated with chemotherapy and/or radiation as adjuvant therapies. Nevertheless, predicting the degree of cancer response to chemotherapy or radiation therapy at diagnosis in order to personalize the clinical approach represents the biggest challenge in locally advanced cancers. The feasibility of such predictive models has been repeatedly assessed using histopathological factors, imaging and nuclear methods, tissue and fluid scans, however with poor results. In this context, the identification of novel potential biomarkers remains an unmet clinical need, and microRNAs (miRNAs) represent an interesting opportunity. With this in mind, the aim of this systematic review was to map the current literature on tumor and circulating miRNAs identified as significantly associated with the therapeutic response in cervical cancer; finally, a perspective point of view sheds light on the challenges ahead in this tumor. Systematic Review Registration: PROSPERO (CRD42021277980).
Copyright © 2022 Ravegnini, Gorini, Dondi, Tesei, De Crescenzo, Morganti, Hrelia, De Iaco, Angelini and Perrone.

Entities:  

Keywords:  HPV; cervical cancer; chemotherapy; miRNAs; radiotherapy; therapeutic response

Year:  2022        PMID: 35747791      PMCID: PMC9209727          DOI: 10.3389/fonc.2022.847974

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   5.738


  46 in total

1.  microRNA-18a, a member of the oncogenic miR-17-92 cluster, targets Dicer and suppresses cell proliferation in bladder cancer T24 cells.

Authors:  Jun Tao; Deyao Wu; Pengchao Li; Bin Xu; Qiang Lu; Wei Zhang
Journal:  Mol Med Rep       Date:  2011-09-20       Impact factor: 2.952

2.  Popping the (PICO) question in research and evidence-based practice.

Authors:  Patricia W Stone
Journal:  Appl Nurs Res       Date:  2002-08       Impact factor: 2.257

3.  Survival after curative pelvic exenteration for primary or recurrent cervical cancer: a retrospective multicentric study of 167 patients.

Authors:  Vito Chiantera; Martina Rossi; Pierandrea De Iaco; Christardt Koehler; Simone Marnitz; Gabriella Ferrandina; Francesco Legge; Fabio Parazzini; Giovanni Scambia; Achim Schneider; Giuseppe Filiberto Vercellino
Journal:  Int J Gynecol Cancer       Date:  2014-06       Impact factor: 3.437

Review 4.  Cervical cancer.

Authors:  Paul A Cohen; Anjua Jhingran; Ana Oaknin; Lynette Denny
Journal:  Lancet       Date:  2019-01-12       Impact factor: 79.321

5.  The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study.

Authors:  H O Smith; M F Tiffany; C R Qualls; C R Key
Journal:  Gynecol Oncol       Date:  2000-08       Impact factor: 5.482

Review 6.  Cervical cancer development, chemoresistance, and therapy: a snapshot of involvement of microRNA.

Authors:  Tandrima Mitra; Selvakumar Elangovan
Journal:  Mol Cell Biochem       Date:  2021-08-28       Impact factor: 3.396

7.  Prognostic Impact of Pretreatment Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography SUVmax in Patients With Locally Advanced Cervical Cancer.

Authors:  Simona Cima; Anna Myriam Perrone; Paolo Castellucci; Gabriella Macchia; Milly Buwenge; Silvia Cammelli; Savino Cilla; Martina Ferioli; Gabriella Ferrandina; Andrea Galuppi; Eugenio Salizzoni; Daniela Rubino; Stefano Fanti; Pierandrea De Iaco; Alessio Giuseppe Morganti
Journal:  Int J Gynecol Cancer       Date:  2018-03       Impact factor: 3.437

8.  A microRNA expression signature for clinical response in locally advanced cervical cancer.

Authors:  Abraham Pedroza-Torres; Jorge Fernández-Retana; Oscar Peralta-Zaragoza; Nadia Jacobo-Herrera; David Cantú de Leon; Jorge F Cerna-Cortés; Cesar Lopez-Camarillo; Carlos Pérez-Plasencia
Journal:  Gynecol Oncol       Date:  2016-07-14       Impact factor: 5.482

9.  microRNA-18a induces apoptosis in colon cancer cells via the autophagolysosomal degradation of oncogenic heterogeneous nuclear ribonucleoprotein A1.

Authors:  M Fujiya; H Konishi; M K Mohamed Kamel; N Ueno; Y Inaba; K Moriichi; H Tanabe; K Ikuta; T Ohtake; Y Kohgo
Journal:  Oncogene       Date:  2013-10-28       Impact factor: 9.867

10.  Down regulation of miR-143 is related with tumor size, lymph node metastasis and HPV16 infection in cervical squamous cancer.

Authors:  Yanxia Chen; Cailing Ma; Wei Zhang; Zhifang Chen; Li Ma
Journal:  Diagn Pathol       Date:  2014-04-28       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.